Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity

[1]  L. Jacks,et al.  Adjuvant trastuzumab with chemotherapy is effective in women with small, node‐negative, HER2‐positive breast cancer , 2011, Cancer.

[2]  Jong-Hyeon Jeong,et al.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  William Chen,et al.  Lack of Uniformity in Cardiac Assessment during Trastuzumab Therapy , 2011, The breast journal.

[4]  J. Forbes,et al.  Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Coombes,et al.  Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Hudis,et al.  Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Winer,et al.  Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Funda Meric-Bernstam,et al.  High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Hortobagyi,et al.  Role of anthracyclines in the treatment of early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Jeff Myers,et al.  High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Lake,et al.  The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[14]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[15]  J. Baselga,et al.  Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Mileshkin,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2012, The New England journal of medicine.

[19]  J. Thigpen.  Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association with Responsiveness to Anthracycline-Based Chemotherapy , 2011 .

[20]  J. Thigpen.  Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens , 2011 .

[21]  T. Vandenberg,et al.  Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. , 2010, Current oncology.